Intercure (INCR) AI Stock Analysis

• Market Cap: $279.65M
• Dividend Yield: N/A
• Average Volume (3M): 44.16K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.05
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: IL
• Employees: 320
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 54,512,608
• 10 Day Avg. Volume: 50,826
• 30 Day Avg. Volume: 44,165
• PEG Ratio: 1.05
• Price to Book (P/B): 0.62
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $539.64
• Price Target Upside: 5.19% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 45 Neutral
• Price Target: 539.00 ▲(5.07%Upside)

Intercure's overall stock score is primarily impacted by poor financial performance, characterized by declining revenues and negative cash flows. The technical analysis offers some mixed signals but does not significantly counterbalance the financial challenges. The absence of clear valuation metrics further weighs down the score.

Intercure Business Overview & Revenue Model

Company Description

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis extract mixed with oil. The company also invests in biomed sector. InterCure Ltd. was incorporated in 1994 and is headquartered in Herzliya, Israel.

How the Company Makes Money

Intercure makes money primarily through the cultivation and sale of medical cannabis products. The company generates revenue by distributing its products through a network of pharmacies and healthcare providers. Key revenue streams include the sale of dried cannabis flowers, cannabis oils, and other derivative products. Intercure also benefits from strategic partnerships and collaborations with other pharmaceutical companies and research institutions, which help expand its market reach and product offerings. Additionally, the company may engage in licensing agreements and partnerships to leverage its expertise and proprietary technologies in other markets.

Intercure Financial Statement Overview

Summary

Intercure is facing financial challenges with declining revenues, negative profitability, and cash flow issues. While the balance sheet shows manageable leverage, the decreasing equity and cash flow difficulties could hinder future growth and stability.

Income Statement

Intercure has experienced a significant decline in revenue and profitability over the reported periods. The gross profit margin decreased, and the company reported negative EBIT and EBITDA margins, indicating operational challenges. Net profit margin is also negative, reflecting ongoing losses.

Balance Sheet

The balance sheet reveals a moderate debt-to-equity ratio, showing some leverage but not excessively high. However, the stockholders' equity has been decreasing, which could be concerning. The equity ratio suggests a fair level of equity financing, but declining equity may pose future risks.

Cash Flow

Intercure's cash flow statement highlights negative free cash flow and operating cash flow, indicating cash flow difficulties. The company also struggles with generating positive cash flow relative to net income, suggesting inefficiencies in cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	238.84M	355.55M	388.68M	219.68M	65.03M
Gross Profit	30.23M	105.09M	155.08M	91.13M	31.98M
EBITDA	-51.31M	-23.90M	70.23M	31.17M	-34.53M
Net Income	-67.80M	-61.96M	44.82M	4.69M	-37.23M
Balance Sheet
Total Assets	762.57M	786.61M	958.01M	686.32M	326.27M
Cash, Cash Equivalents and Short-Term Investments	78.65M	101.33M	232.79M	196.55M	38.26M
Total Debt	211.40M	195.68M	255.16M	108.91M	6.68M
Total Liabilities	364.90M	329.55M	436.53M	227.13M	34.16M
Stockholders Equity	396.97M	455.11M	501.31M	448.03M	274.51M
Cash Flow
Free Cash Flow	-71.30M	-56.25M	31.52M	10.99M	-13.04M
Operating Cash Flow	-66.93M	-53.63M	51.27M	25.02M	7.80M
Investing Cash Flow	17.69M	4.77M	-142.50M	-65.21M	-22.76M
Financing Cash Flow	26.45M	-82.89M	120.45M	203.06M	25.29M

Intercure Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 513.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:INCR, the sentiment is Negative. The current price of 513 is below the 20-day moving average (MA) of 517.17, below the 50-day MA of 540.29, and below the 200-day MA of 568.67, indicating a bearish trend. The MACD of -6.68 indicates Negative momentum. The RSI at 44.49 is Neutral, neither overbought nor oversold. The STOCH value of 44.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:INCR.

Intercure Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	57 Neutral	£4.89B	6.73	-62.36%	5.46%	34.03%	6.31%
INCR	45 Neutral	$279.65M	―		―	―	―
TGTR	―	64.98M	128.29		―	―	―
UNVO.M	―	3.06M	―		―	―	―
TKUN	―	32.97M	―		―	―	―
GEFR	―	147.45M	―		―	―	―
SEMG	―	93.48M	6.42		4.24%	―	―

Intercure Corporate Events

InterCure Announces Leadership Change and Secures $18.2 Million Financing

InterCure Ltd. announced significant leadership changes and financial advancements. Ehud Barak is stepping down as Chairman, to be succeeded by CEO Alexander Rabinovich, who has led the company through substantial growth. InterCure has completed a financing round, securing approximately $18.2 million to support the recovery and expansion of its Nir Oz facility, with potential additional funds from warrants. The company is focused on executing a recovery plan post-war, aiming to restore operations and continue its expansion in international markets such as Germany, the UK, and Australia. This financing and leadership transition are strategic moves to ensure long-term stability and growth, positioning InterCure as a significant player in the pharmaceutical cannabis industry.

Intercure Releases Detailed Land and Financial Report

Intercure has released a detailed report concerning its land, which includes analyses of the company’s operations and economic situation, as well as its business results. The report reveals financial data, highlighting the issuance of 7,349,896 ordinary shares, with an equal number expected to be issued in the future, indicating the company’s ongoing financial activities.